Anchor Investment Management LLC Sells 133 Shares of Amgen Inc. (NASDAQ:AMGN)

Anchor Investment Management LLC trimmed its position in Amgen Inc. (NASDAQ:AMGN) by 2.1% during the third quarter, according to its most recent 13F filing with the SEC. The fund owned 6,078 shares of the medical research company’s stock after selling 133 shares during the period. Anchor Investment Management LLC’s holdings in Amgen were worth $1,958,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Lantz Financial LLC raised its holdings in Amgen by 5.1% during the 2nd quarter. Lantz Financial LLC now owns 1,779 shares of the medical research company’s stock worth $556,000 after purchasing an additional 87 shares during the last quarter. Fiduciary Financial Group LLC acquired a new stake in shares of Amgen during the 2nd quarter worth approximately $390,000. Silver Lake Advisory LLC raised its stake in shares of Amgen by 38.5% during the second quarter. Silver Lake Advisory LLC now owns 1,076 shares of the medical research company’s stock worth $336,000 after buying an additional 299 shares during the last quarter. Triad Wealth Partners LLC bought a new position in Amgen in the second quarter valued at approximately $128,000. Finally, Miracle Mile Advisors LLC grew its holdings in Amgen by 5.2% during the 2nd quarter. Miracle Mile Advisors LLC now owns 5,168 shares of the medical research company’s stock worth $1,615,000 after acquiring an additional 254 shares during the period. 76.50% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have weighed in on AMGN. William Blair reissued an “outperform” rating on shares of Amgen in a research note on Tuesday, November 12th. UBS Group lowered their price objective on shares of Amgen from $335.00 to $326.00 and set a “neutral” rating for the company in a research report on Thursday, October 31st. Deutsche Bank Aktiengesellschaft decreased their target price on Amgen from $305.00 to $285.00 in a research note on Wednesday, November 27th. Leerink Partners dropped their price target on Amgen from $349.00 to $302.00 in a research report on Wednesday, November 27th. Finally, Royal Bank of Canada decreased their price objective on Amgen from $360.00 to $330.00 and set an “outperform” rating for the company in a research report on Wednesday, November 27th. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $319.68.

Amgen Stock Up 0.2 %

NASDAQ:AMGN opened at $274.06 on Friday. Amgen Inc. has a twelve month low of $257.80 and a twelve month high of $346.85. The firm has a market capitalization of $147.32 billion, a price-to-earnings ratio of 35.09, a price-to-earnings-growth ratio of 3.02 and a beta of 0.55. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55. The stock’s 50 day moving average price is $303.87 and its two-hundred day moving average price is $315.16.

Amgen (NASDAQ:AMGN) last issued its earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, topping analysts’ consensus estimates of $5.11 by $0.47. The business had revenue of $8.50 billion for the quarter, compared to the consensus estimate of $8.50 billion. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The firm’s revenue for the quarter was up 23.2% on a year-over-year basis. During the same period in the previous year, the company earned $4.96 earnings per share. Equities research analysts expect that Amgen Inc. will post 19.51 earnings per share for the current fiscal year.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be paid a $2.38 dividend. This is an increase from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 annualized dividend and a yield of 3.47%. The ex-dividend date of this dividend is Friday, February 14th. Amgen’s dividend payout ratio (DPR) is 121.90%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.